COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group (2024)
- Authors:
- Autor USP: SHINJO, SAMUEL KATSUYUKI - FM
- Unidade: FM
- DOI: 10.1007/s00296-023-05496-y
- Subjects: COVID-19; DIABETES MELLITUS; VACINAÇÃO; ESTUDOS TRANSVERSAIS
- Language: Inglês
- Imprenta:
- Publisher place: Heidelberg
- Date published: 2024
- Source:
- Título: Rheumatology international
- ISSN: 0172-8172
- Volume/Número/Paginação/Ano: v. 44, n. 1, p. 73-80, 2024
- Este artigo possui versão em acesso aberto
- URL de acesso aberto
- PDF de acesso aberto
- Versão do Documento: Versão publicada (Published version)
-
Status: Artigo aberto em periódico híbrido (Hybrid Open Access) -
ABNT
PANCHAWAGH, Suhrud et al. COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group. Rheumatology international, v. 44, n. 1, p. 73-80, 2024Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/58770. Acesso em: 14 mar. 2026. -
APA
Panchawagh, S., Ravichandran, N., Barman, B., Nune, A., Javaid, M., Gracia-Ramos, A. E., et al. (2024). COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group. Rheumatology international, 44( 1), 73-80. doi:10.1007/s00296-023-05496-y -
NLM
Panchawagh S, Ravichandran N, Barman B, Nune A, Javaid M, Gracia-Ramos AE, Day J, Joshi M, Kuwana M, Shinjo SK. COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group [Internet]. Rheumatology international. 2024 ; 44( 1): 73-80.[citado 2026 mar. 14 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58770 -
Vancouver
Panchawagh S, Ravichandran N, Barman B, Nune A, Javaid M, Gracia-Ramos AE, Day J, Joshi M, Kuwana M, Shinjo SK. COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group [Internet]. Rheumatology international. 2024 ; 44( 1): 73-80.[citado 2026 mar. 14 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58770 - High prevalence of necrotizing myofibers in adult dermatomyositis muscle biopsies
- Rituximab as a treatment for human immunodeficiency virus-associated nemaline myopathy: What does the literature have to tell us?
- Clinical manifestations, outcomes, and antibody profile of Brazilian adult patients with dermatomyositis: a single-center longitudinal study
- Long-term effects of early pulse methylprednisolone and intravenous immunoglobulin in patients with dermatomyositis and polymyositis
- Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys
- Type 1 diabetes, COVID-19 vaccines and short-term safety: Subgroup analysis from the global COVAD study
- Cardiovascular manifestations in idiopathic inflammatory myopathies
- Flares after COVID-19 infection in patients with idiopathic inflammatory myopathies: results from the COVAD study
- Vaccine hesitancy in patients with autoimmune diseases. [Carta]: data from the coronavirus disease-2019 vaccination in autoimmune diseases study
- Different clinical phenotypes in anti-melanoma differentiation-associated protein 5-associated positive dermatomyositis
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
